2006

Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations

Sewell, GJ

<http://hdl.handle.net/10026.1/3724>

10.1177/1078155206070439

Journal of Oncology Pharmacy Practice

SAGE Publications

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations

Sarah Roberts, Bsc¹

Nancy Khammo, PhD²

Gerald McDonnell, PhD²

Graham J Sewell, PhD, BPharm³

Objective. The aim of this study was to examine the removal and deactivation of cytotoxic contamination from surfaces of a pharmaceutical isolator workstation.

Methods. Three marker cytotoxic drugs were evaluated in three phases using decontamination technologies currently available in the pharmaceutical and healthcare environments. Phase I investigated the physical removal of contamination by detergents. Phase II and III investigated the effectiveness of detergents and Vaporised Hydrogen Peroxide (VHP®) in degrading cytotoxic drugs, respectively.

Results. 5-Fluorouracil, doxorubicin and cyclophosphamide were removed from a surface by wiping with detergents. VHP® and alkaline detergents caused degradation of doxorubicin. The observed effect with detergent cleaning was pH dependent, but neither of the technologies applied had any effect on the chemical stability of 5-fluorouracil and cyclophosphamide under the conditions tested. *J Oncol Pharm Practice* (2006) 12: 95–104.

Key words: cyclophosphamide; cytotoxic; decontamination; degradation; doxorubicin; 5-fluorouracil; vaporized hydrogen peroxide

INTRODUCTION

Chemotherapy is the only systemic treatment modality for cancer. However, cytotoxic drugs are not selective for cancer cells, but also effect the growth and reproduction of healthy cells. During the preparation of cytotoxic infusions, a variety of drug manipulations are performed, resulting in the generation of aerosols and droplets, which are known to contaminate the areas in which they disperse into, including isolators and surrounding surfaces.^{1–9} This

increases the risk of occupational exposure to these drugs, for which the health effects are well documented.^{10–13}

The effectiveness of removing cytotoxic residues from surfaces during cleaning is not often considered. Ideally, removing cytotoxic contamination should involve the physical removal of drug contamination from a surface and drug breakdown into less toxic compounds. Cytotoxic drugs represent a diverse range of chemical structures, and no single agent is known to deactivate all the cytotoxic drugs currently used. Therefore, decontamination is limited to the mechanical removal from a non-disposable surface to a disposable surface, ie, by wiping the working surface with a cleaning agent. The National Institute for Occupational Health and Safety (NIOSH) recommends that all surfaces are decontaminated according to a protocol, which includes an appropriate deactivation agent if available.¹⁴ The agent used should preferably demonstrate removal/breakdown

From the ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; ²Steris Ltd, Basingstoke, Hampshire, UK; ³Department of Pharmacy, Kingston University, Kingston-Upon-Thames, Surrey, UK

Address correspondence and reprint requests to Professor GJ Sewell, Department of Pharmacy, Kingston University, Penrhyn Road, Kingston, Surrey, KT1 2EE, UK
E-mail: g.j.sewell@kingston.ac.uk

Received 1 March 2006; accepted 12 June 2006

of biological and chemical contamination.¹⁴ Currently, the most prevalent practice consists of surface wiping with water, with or without a detergent, with thorough rinsing, followed by wiping with 70% alcohol.

In 1985, the International Agency for Research on Cancer (IARC) included cytotoxic drugs in its program for the treatment of contaminated waste,¹⁵ and oxidation was suggested as a method for degrading these compounds. Studies carried out to investigate the efficacy of oxidizing agents used in hospitals showed sodium hypochlorite (5.25%) was >99.96% efficient at degrading several drugs, including cyclophosphamide and doxorubicin. Liquid hydrogen peroxide (30%) was also successful.^{16,17}

The aim of this study was to investigate the safe decontamination of areas used for the dispensing of cytotoxic drugs, by evaluating systems that remove and deactivate cytotoxic contamination from the surface of an isolator workstation. Decontamination may be defined as the use of physical and/or chemical means to render a surface or item safe for handling, use or disposal. This can refer to both chemical and biological decontamination, which are important in the safe dispensing of cytotoxic drugs. Decontamination is generally a combination of cleaning (to physically remove surface contamination) and disinfection/sterilization (which are anti-microbial processes).

The effects of two decontamination technologies currently in practice, ie, vaporised hydrogen peroxide (VHP®) and liquid detergents, on three marker cytotoxic drugs were evaluated.

VHP® is an odourless, colourless gas that is produced by vaporization of liquid hydrogen peroxide to give a mixture of hydrogen peroxide and water vapour. The systems used to generate VHP® were based on the delivery of a 'dry' (or non-condensed) hydrogen peroxide gas within a given area.¹⁸ In this gaseous state, the biocidal and surface compatibility properties are markedly superior to liquid hydrogen peroxide.¹⁹ The liquid detergents were formulations scientifically designed for the removal of specific material, eg, protein- or mineral-based material from various surfaces, and are in current use for various hospital and pharmaceutical applications.

The decontamination of cytotoxic drugs on surfaces using the decontamination technologies currently available was investigated. The aim was not only to investigate the removal of the drugs, but also the effects of detergents and biocides tested in the

interaction or break-down of the drugs into safe by-products. This was evaluated in three phases:

Phases I and II investigated the effectiveness of aqueous-based detergents across a pH range of 1.7–13.2, as cleaning agents, which could be incorporated into a cleaning protocol;

Phase I – The physical removal of contamination from a surface by wiping with the detergents;

Phase II – The ability of the detergents as deactivating agents.

Phase III investigated the ability of VHP® to degrade the drugs on an inert surface by oxidation.

The three marker cytotoxic drugs used in this study were from different drug classes: 5-fluorouracil (5-FU, an anti-metabolite), cyclophosphamide (CP, an alkylating agent) and doxorubicin (DOX, an anthracycline antibiotic). These drugs are commonly used in the treatment of cancer and their sensitivity to degradation by various mechanisms is well documented.

MATERIALS

5-FU (250 mg/10 mL) and DOX (2 mg/mL) were obtained from Mayne Pharma Plc (Leamington Spa, UK); CP (500 mg) was obtained from Pzifer Ltd (Sandwich, UK). The test surface used in this study was made 'in-house' from the barrel of polypropylene syringes (Beckton and Dickinson, UK). Centrifuge (15 mL) tubes were obtained from Sarstedt (Leics, UK). Liquid hydrogen peroxide (Vaprox®), VHP 100P generator (Serial No. 0135103–29), flexible walled isolator, chemical indicators (Chemdi VHP code: NB305), and detergents (CIP 100, CIP 150, Criti-Klenz, Renu-Klenz, NpH-Klenz, Cage-Klenz 250, CIP 200 and CIP 220) were supplied by STERIS Corporation (Basingstoke, UK). Acetonitrile, disodium hydrogen orthophosphate, methanol, potassium dihydrogen orthophosphate were purchased from Fisher Scientific (Leics, UK). Ammonium sulphate, perchloric acid, sodium chloride and sulphuric acid were purchased from BDH (Poole, UK). Normal saline (NS) and sterile water for injections (WFI) were obtained from Baxter (Newbury, UK). Industrial methylated spirit (IMS) was obtained from Shield Medicare (Surrey, UK). All chemicals and reagents used for high-performance liquid chromatography (HPLC) were of analytical grade or (HPLC) grade. Hydrogen peroxide detection tube and hand held pump (Accuro®) were obtained from Dräger (UK). The HPLC system comprised of an isocratic

constaMetric 3200 pump (LDC analytical), autosampler 851-AS (Jasco) and a variable wavelength UV detector (Applied Biosystems). Data analysis was performed using Prime software, version 4.2.0 (HPLC Technology, Herts, UK). HPLC columns were purchased from Phenomenex (Cheshire, UK) and HPLC Technology (Herts, UK).

METHODOLOGY

Cytotoxic drug preparations, surface coating of test surfaces and Phase I and II of the study were carried out in a class II biological safety cabinet (BSC). Exposure of the drug to VHP[®] was carried out in a flexible-walled isolator.

Choice of diluent

All three marker drugs were reconstituted or diluted in two common clinical diluents; WFI, NS and the HPLC buffer specific for each drug assay, ie, phosphate buffer (0.01 M, pH 7.0) was used for 5-FU; ammonium sulphate buffer (0.01 M, pH 3.5) was used for CP; and sodium chloride (0.01 M, pH 2.25) was used for DOX, to study any pH effect. Phase I, which involved removal by wiping was carried out on the drugs diluted in WFI and NS. In Phase II tests, WFI was used, and for Phase III, all diluents were used. Method validation was carried out with all diluents to take into account any variation in HPLC detector response.

Drug reconstitution

All cytotoxic drugs were diluted or reconstituted to the working concentration. 5-FU (25 mg/mL) was diluted in all three diluents to give a final concentration of 5 mg/mL, and 10 µL was transferred onto the test surface. The final concentration for assay was 10 µg/mL. CP (500 mg) was reconstituted in all three diluents to give a final concentration of 20 mg/mL, and 20 µL was transferred onto the test surface. The final concentration for assay was 400 µg/mL. DOX (2 mg/mL) was diluted to 1 mg/mL in all three diluents, and 10 µL was transferred onto the test surface. The final concentration for assay was 10 µg/mL.

Test surface coating

The test surface was made by transverse sectioning through a barrel of a 5-mL polypropylene syringe at 2-cm intervals. The resulting rings were then cut in half, giving rectangular surfaces of 2 × 1.2 cm. Polypropylene, an inert surface, was used to eliminate

any contribution from the surface on the tests carried out. The surfaces were coated by placing between 10 and 20 µL of drug solution on the concave side of the surface. Surface controls included coating with diluent only and blank non-coated surfaces. All test surfaces (including blank) were allowed to dry in the BSC for 2 hours (until no solution remained). For Phase I, the surfaces were treated in the BSC and for Phase III, the surfaces were placed horizontally in the centre of the isolator, on a flat plastic tray, elevated at approximately 30 cm above ground level.

Drug recovery

Each test surface was placed into a centrifuge tube containing HPLC buffer specific for each drug (described in choice of diluent). The tubes were centrifuged for 5 minutes at 1500 × *g*. The supernatant was transferred to an autosampler vial for assay by HPLC. Recovery was determined at the experimental sample concentration. The desorption of dried drug from the polypropylene test surface into the desorbing solution (HPLC buffer) was measured against a standard (taken as 100%) which had not been subjected to these conditions (Table 1).

HPLC methods

HPLC methods,^{20–22} were validated and used to quantify the amount of the parent drug remaining after all three study phases. For each assay, the flow rate was 1 mL/min, and 100 µL was injected onto the column.

5-FU: Columbus C18, 5 µm, 150 × 4.6 mm column and 0.01 M phosphate buffer (pH 7.0) containing 5% methanol as the mobile phase. A wavelength of 270 nm was used.

DOX: Techsphere C₁₈, 5 µm, 150 × 4.6 mm column and 0.01 M sodium chloride buffer (pH 2.25) containing 40% acetonitrile as the mobile phase. A wavelength of 254 nm was used.

CP: Techsphere CN, 5 µm, 250 × 4.6 mm column and 0.01 M ammonium sulphate buffer (pH 3.5) containing 30% methanol as the mobile phase. A wavelength of 210 nm was used.

HPLC method validation results for each assay in all three diluents are shown in Table 1.

Precision was measured as the coefficient of variation (cv) of the experimental sample concentration. Five samples were prepared and assayed on the same day (intra-day) and one sample was prepared and analysed on 5 separate days (inter-day) by HPLC. Precision was accepted if cv > ±15%.²³

Table 1. HPLC method validation results for 5-FU, DOX and CP in three diluents

	Cytotoxic drug		
	5-FU	DOX	CP
Limit of detection	0.2 µg/mL ^a	0.25 µg/mL ^a	2.5 µg/mL ^a
Limit of quantification	0.5 µg/mL ^a	1 µg/mL ^a	10 µg/mL ^a
Mean recovery (<i>n</i> =5)	NS = 95.9%	NS = 99.9%	NS = 100.4%
	WFI = 98.8%	WFI = 99.8%	WFI = 96.0%
	Buffer = 98.5%	Buffer = 100.0%	Buffer = 96.3%
Linearity regression coefficient	NS: $R^2 = 0.999$	NS: $R^2 = 0.999$	NS: $R^2 = 0.999$
	WFI: $R^2 = 0.999$	WFI: $R^2 = 1$	WFI: $R^2 = 0.998$
	Buffer: $R^2 = 0.999$	Buffer: $R^2 = 0.999$	Buffer: $R^2 = 0.997$
Intra-day precision (<i>n</i> =5)	NS: cv = 1.1%	NS: 0.4%	NS: 1.6%
	WFI: cv = 1.3%	WFI: 1.7%	WFI: 1.4%
	Buffer: cv = 0.7%	Buffer: 1.9%	Buffer: 2.2%
Inter-day precision (<i>n</i> =5)	NS: cv = 1.9%	NS: cv = 2.5%	NS: cv = 2.2%
	WFI: cv = 3.5%	WFI: cv = 0.4%	WFI: cv = 3.1%
	Buffer: cv = 1.5%	Buffer: cv = 2.3%	Buffer: cv = 3.9%

^aApplicable to all diluents.

Linearity was evaluated around the expected concentration range. A correlation coefficient (R^2) > 0.99 was indicative of linearity when combined with visual inspection of the plot.

Chemical basis of the detergents (formulations)

A range of detergents (acid, neutral, alkali) was used in the study. The importance of their use is that, unlike single chemical solutions, all detergents used are composed of a series of components – such as acid/alkali/neutral base, pH regulators, oxidizing agents, chelators, surfactants and solubilizing agents – which work together to not only clean a specific target soil, such as protein from a surface, but to provide an optimum environment for the cleaning agents to work. Major components of the acidic formulations used were hydroxyacetic acid (CIP 220), phosphoric and citric acid (CIP 200), citric acid (Cage-Klenz). The neutral formulations, such as Renu-Klenz and NpH-Klenz, and the alkaline formulation, Criti-Klenz, contain high levels of surfactants, whereas the remaining alkaline formulations were potassium hydroxide, sodium hypochlorite (CIP 150) and potassium hydroxide (CIP 100) based.

Phase I: physical removal by detergents

The ability of eight detergents was investigated for their effects when used in a wipe study to physically remove dried cytotoxic drug from the test surface. WFI and IMS were used as the controls. For each detergent, 50 µL was pipetted onto a cytotoxic-coated surface and control test surface. Wiping involved one

stroke across the test surface. The area was wiped immediately. If the drug remained on the surface, ie, the amount remaining was above the limit of detection of the method, a second surface of the same drug was wiped twice. If still above the limit of detection, a third surface of the same drug was wiped three times. The remaining drug was then recovered from the wiped test surface and analysed by HPLC.

Phase II: deactivation by detergents

The ability of the same eight detergents to degrade the three cytotoxic drugs was investigated using a modification of the suspension test, as set out in British Standard (BS EN 1656; 2000; 22). A 35% (Vaprox[®]) liquid hydrogen peroxide solution was also included to compare with the gaseous activity. A solution (100 µL) of test drug was mixed with an equal volume (100 µL) of diluted detergent or Vaprox[®] at room temperature. The solution was vortexed for 1 minute, then incubated at 22–23°C for up to 60 minutes. Following incubation, 800 µL of HPLC assay buffer was added to terminate the action of the detergent. IMS was used as a control. The amount of parent drug remaining in the resulting mixture was quantified by HPLC. The drugs were subjected to extreme levels of pH, ranging from 1.7 to 13.2 (Table 2).

Phase III: deactivation by VHP[®]

VHP[®] delivery and control systems have been developed to provide a consistent fumigation process for a given area.²³ VHP[®] was generated using 35% liquid hydrogen peroxide (Vaprox[®]) inside a VHP[®]

Table 2. Dilution and pH of detergents, Vaprox® and IMS

	Detergents									
	CIP 100	CIP 150	Criti-Klenz	Renu-Klenz	NpH-Klenz	CIP 220	Cage-Klenz	CIP 200	Vaprox®	IMS
Dilution (%) ^a	0.8	0.8	1.6	1.6	1.6	1.6	1.6	1.6	35	70
pH	13.2	12.8	11.3	8.0	7.5	2.4	2.3	1.7	2.6	5.5

^aAll reagents used were diluted in distilled water based on manufacturers instructions, except for Vaprox®.

100P bio-decontamination system. The VHP® 100P is a mobile system which, when connected to a given area, controls the whole dry fumigation process (Figure 1). A typical VHP® decontamination cycle consists of four phases: dehumidification, conditioning, decontamination and aeration (cycle conditions are given in Table 3). The exposure was carried out in a flexible walled isolator with an area of 1 m³. Prior to each cycle, a leak test was carried out to ensure that the flexible isolator was leak proof. Chemical indicators were placed evenly within the isolator to confirm an even distribution of VHP®. During the course of the cycle, room and isolator temperatures were monitored for signs of condensation within the isolator. If condensation appeared, the cycle was aborted. Following exposure to VHP®, the drug was recovered from the test surfaces and quantified by HPLC.

Figure 1. Front view of a mobile VHP 100P unit, which delivers dry hydrogen peroxide vapour.

RESULTS

HPLC method validation

Validated HPLC methods for all three drugs in three diluents were used to quantify the amount of drug remaining after each test (Table 1).

Recovery from the drug-coated surfaces was very high (>95%). The methods are reproducible with a coefficient of variation of <2.2% for intra- and <3.9% inter-day precision. This applies to all three drugs in three diluents.

Linearity was demonstrated over the concentration range of 0.5–30 µg/mL for 5-FU, 10–700 µg/mL for CP, and 1–20 µg/mL for DOX. Peak area (*y*) plotted against concentration (*x*) gave a correlation coefficient (*R*²) > 0.99, demonstrating a linear relationship between *x* and *y*.

Phase I: physical removal by detergents

5-FU and CP were easily removed from the test surface when using a dry wipe, with acid, neutral or alkaline detergent (Table 4). DOX was easily removed with acid or neutral detergent, but was more persistent to removal by alkaline detergents, requiring more than one wipe to remove all traces (not quantifiable).

Table 3. VHP® cycle parameters

Parameter	Value
Dehumidification	
– Airflow (m ³ /h)	18
– Absolute humidity (mg/L)	2.3
– Time (min)	10
Conditioning	
– Airflow (m ³ /h)	12
– Injection rate (g/min)	2.5
– Time (min)	3
Decontamination	12
– Airflow (m ³ /h)	1.6
– Injection rate (g/min)	25
Aeration	
– Airflow (m ³ /h)	18
– Time (min)	90

Table 4. Decontamination by detergents (removal by wiping)

Test	No. of wipes required to remove drug					
	5-FU (WFI)	5-FU (NS)	CP (WFI)	CP (NS)	DOX (WFI)	DOX (NS)
WFI	1	3	1	1	1	1
Criti-Klenz	1	1	1	1	2	2
CIP 150	1	1	1	1	3	3
CIP 100	1	1	1	1	2	2
Renu-Klenz	1	1	1	1	1	1
Nph-Klenz	1	1	1	1	1	1
Cage-Klenz	1	1	1	1	1	1
CIP 220	1	1	1	1	1	1
CIP 200	1	1	1	1	1	1
IMS	1	1	1	1	1	1

An immediate colour change from red to purple was evident when the three alkaline detergents were added to DOX. The depth of purple increased with increasing alkalinity of the detergents. This colour change was not observed with the controls (WFI and IMS).

Wiping with WFI and IMS was effective in removing all three drugs. All detergents were superior over WFI when removing 5-FU diluted in NS.

Phase II: deactivation by detergents

5-FU and CP demonstrated resistance to decomposition across the pH range following 60 minutes of exposure to all detergents and liquid hydrogen peroxide. DOX was resistant to degradation at acid and neutral pH up to and including 60 minutes. However, significant degradation of DOX was observed with alkaline detergents, the rate increasing with increasing alkalinity. The rate of degradation of DOX by alkaline detergents is shown in Figure 2.

The rate of degradation of DOX can be described by the equation $y = -0.0089x + 1.9773$, $R^2 = 0.934$, and has a half-life of 31.3 minutes when exposed to Criti-Klenz.

Degradation by CIP 150 can be described by the equation $y = -0.0055x + 1.8847$, $R^2 = 0.904$, with a half-life of 33.8 minutes. Degradation by CIP 100 can be described by the equation $y = -0.009x + 1.7485$, $R^2 = 0.847$, with a half-life of 5.5 minutes.

A colour change from red to deep purple was also observed upon the addition of alkaline detergents to DOX. The depth of purple increased with increasing pH of the detergents. This was not observed with acidic- or neutral-based detergents or IMS. Temperatures, which did not exceed 24°C throughout the study, had no effect on the controls and, therefore, did not contribute to any degradation. All three drugs

showed no degradation after exposure to liquid hydrogen peroxide for 60 minutes.

Phase III: deactivation by VHP®

The decontamination cycle with the VHP® was successfully completed. All chemical indicators changed colour from blue to beige during the exposure of all three drugs tested, demonstrating the presence of VHP® throughout the flexible isolator and the use of a successful validated cycle. Internal isolator temperature readings did not rise above 30°C, and external air temperature did not rise above 28°C. No condensation was predicted or evident inside the isolator at any point throughout the duration of the exposures. VHP® had no effect on the blank and control test surfaces in the study. Furthermore, there was no evidence of degradation of DOX in control test surfaces from the effect of natural light or temperature throughout the cycle duration (Table 5).

VHP® had little or no effect on 5-FU under the conditions tested. The peak area of all measurements was slightly lower than the range of accuracy of the method, but no degradation products or significant decrease in LC peak height was observed. Similarly, VHP® had no significant effect on CP. The peak area of CP diluted in buffer was slightly lower than the range of intra-day accuracy of the method; but no degradation products or decrease in peak height was observed. VHP® did cause significant degradation of DOX. The amount of degradation was dependent on the diluent used, ie, 43.4% degradation with WFI (pH 5.9), 56.0% with NS (pH 6.5), and 91.9% with buffer (pH 2.25). No colour change of DOX was observed with VHP® exposure.

Figure 3 shows a chromatogram of DOX in buffer pre-exposure (upper chromatogram) and post-exposure (lower chromatogram) to VHP®. Degradation products were not identified or quantified.

Figure 2. Amount of doxorubicin remaining after exposure to alkaline detergents.

CONCLUSION AND DISCUSSION

Many cytotoxic drugs are manipulated in clinical practice and reports of contamination by aerosols, spillages and droplets are highlighted in the literature.^{3,8} This study was set up as a pilot study to investigate the effect of current decontamination technologies (VHP[®] fumigation and liquid detergents) as potential agents which could reduce the risk to the operator by reducing or eliminating drug contamination from a surface.

Three different cytotoxic drugs were exposed to detergents (Phase I and II) and VHP[®] (Phase III). Inert polypropylene test surfaces were coated with

the drugs for Phases I and III. High recovery methods from the test surfaces, together with reliable HPLC methods, were developed, validated and successfully used to quantify the amount of drug remaining after testing in this study.

Preliminary wipe tests using strong alkaline, acid, or neutral detergents, and wiping with a dry wipe removed all three drugs from a contaminated surface. WFI and IMS, the controls, were also efficient. DOX was more persistent to removal, but less persistent to breakdown (indicated by a colour change) by alkaline detergents. The depth of colour change was alkaline-pH dependent.

Exposure of drug solution for up to 1 hour in strong acid and alkali and neutral-based detergents caused no degradation of 5-FU and CP. Degradation of DOX occurred when it was subjected to alkaline pH following 1 hour of incubation. This resulted in 81% degradation at pH 13.2, with 50% occurring after 5.5 minutes.

The results showed that VHP[®] had little to no significant effect on 5-FU or CP, however, degradation was observed with DOX. The degree of degradation was dependent on the diluent used, with significant degradation obtained when DOX was exposed following dilution in a strongly acidic buffer (pH 2.25). Further studies are in progress to investigate the effects of VHP[®] over longer exposure times and higher concentrations against all three drug types. It is interesting to note that liquid hydrogen peroxide, in contrast to gaseous peroxide had no effect on drug

Table 5. VHP[®] exposure assay results

Drug	Exposure	Drug remaining after exposure (%)
5-FU in WFI	VHP	97.9
5-FU in NS	VHP	96.5
5-FU in buffer	VHP	99.1
CP in WFI	VHP	98.7
CP in NS	VHP	97.7
CP in buffer	VHP	94.1
DOX in WFI	VHP	56.6
DOX in WFI	Control (light)	102.4
DOX in WFI	Control (temperature)	101.0
DOX in NS	VHP	44.0
DOX in NS	Control (light)	98.9
DOX in NS	Control (temperature)	100.0
DOX in buffer	VHP	8.1
DOX in buffer	Control (light)	90.1
DOX in buffer	Control (temperature)	97.9

Figure 3. Example of a chromatogram of doxorubicin diluted in buffer, pre- and post-exposure to VHP®.

decomposition. The gaseous form of peroxide has been proposed to be a more effective oxidizing agent due to its unstable nature compared to liquid peroxide.²⁶

This study confirms the stability of 5-FU and CP to oxidative stress, since no decomposition occurred during exposure to gaseous and liquid hydrogen peroxide, even when exposed to extreme pH conditions (pH 1.7–13.2) applied. DOX, however, was found to be less stable. The susceptibility of DOX to oxidation is reported in the literature,²⁴ it is also unstable at pH values <3 or >7.²⁵ In this study, DOX was susceptible to oxidation by VHP®, and its instability at lower pH confirmed.

Exposure of DOX to alkaline-based liquid agents resulted in a colour change from red to purple, which is indicative of decomposition. DOX was susceptible to both VHP® and alkaline agents, indicating that the degradation of DOX was occurring through two different mechanisms, oxidation as one method and

alkali hydrolysis as the other method. No colour change was evident with oxidation.

The results presented are not in total agreement with the literature.^{16,17} Sodium hypochlorite (5.25%) and <30% hydrogen peroxide have been reported to exhibit >98% efficiency in inactivating CP after 1 hour of exposure. DOX was also completely degraded by sodium hypochlorite. The detergent CIP 150 also contains sodium hypochlorite (<5%), however, no effect was observed on CP or DOX with CIP 150, or on CP with the 35% liquid hydrogen peroxide used in this study. These results should be investigated further.

Phase I was carried out following a review of drug structures. Alkaline hydrolysis appeared to be the likely method of degradation of 5-FU in solution. A range of alkaline-based detergents was tested. Degradation of 5-FU through alkaline hydrolysis is reported to be a slow process, leading to the formation of barbituric acid, which degrades

more rapidly than it is formed, and uracil, which further degrades to urea.²⁷ None of the degradation products are cytotoxic. The rate of alkaline hydrolysis increases above pH 9.0.²⁴ Thermal and photochemical degradation causes opening of the pyrimidine ring to produce urea. To date, there is no satisfactory method for the deactivation of 5-FU.

CP degradation occurs primarily by hydrolysis in aqueous solution. The rate is constant over the pH range 2–10. Specific acid and specific base catalysis occurs at extreme pH.²⁷ Under acidic conditions, hydrolysis may occur by different pathways. The pathway and breakdown products formed depend upon the pH of the solution.²⁷ Under basic or neutral conditions, hydrolysis occurs by an initial intramolecular alkylation, forming a bicyclic compound and hydrochloric acid.²⁷ However, this compound is very labile in aqueous solution and may breakdown to further products.²⁷ CP is temperature sensitive and hydrolysis may occur rapidly at temperatures above 30°C.

DOX exhibits pH-dependent stability in solution. It is sensitive to light and temperature. In solutions of pH < 4, the glycosidic bond is cleaved, releasing a red water-soluble amino sugar (daunosamine),²⁵ and a water-insoluble tetracyclic aglycone (doxorubicinone). The aglycone is cytotoxic, but less so than the parent drug.²⁴

In alkaline solution, a colour change from red to deep purple is due to rapid degradation of the drug.²⁴ It is thought to reflect cleavage of the amino sugar and the formation of other degradation products, such as 7,8-dehydro-9,10 desacetyl-daunorubicinone.²⁴ This colour change also occurs with the other anthracyclines antibiotics which are structurally similar.^{24,25}

The results of this study demonstrate that current decontamination methods can be used to reduce, if not eliminate, the risk posed by cytotoxic drugs to the operator and environment. The extent of risk reduction or elimination will vary depending on the structure of the drug. Oxidation and alkaline-based detergents have resulted in the breakdown of DOX by two different mechanisms. Oxidation and alkaline hydrolysis may be used to investigate their effects on drugs of the same anthracycline family as DOX. However, limited success was observed with the chemical deactivation technologies used in this study when applied to drugs representing the other classes, ie, the alkylating agents and the anti-metabolites. Further studies are required to investigate these classes of drugs. The liquid detergents used in this

study were formulated for specific target soil. It may be necessary to vary the formulation to target the more stable structures of 5-FU or CP.

The solubility of a drug depends upon the extent to which it is ionized. This is determined by the pKa of any acidic and basic groups and the pH of the environment. The drugs are more soluble and likely to be taken up by a wipe at the pH at which they are 100% ionized. DOX is ionized at low pH and was easier to remove from the surface with acid rather than alkali detergents, however alkaline detergents played a part in DOX degradation.

All three drugs used in this study are polar molecules ($\log P < 1$) and were removed from a coated surface by water and aqueous-based detergents. Most cytotoxic drugs are water-soluble, therefore, it is recommended that decontamination is removal by the use of wipes impregnated with an aqueous-based agent, which binds the target drug, followed by disposal of the wipe. A combination of agents will be required to cover removal, ie, it is possible that a high pH may degrade the drug to compounds that are more soluble and are easier to remove at low pH. Wiping with IMS is common practice, but may also play a part in the removal of less water-soluble drugs and drug degradation products.

From this study, it is suggested that a review of cleaning practices should be carried out and a protocol developed based on the recommendation that after cleaning with water, surfaces should be cleaned with detergent of high pH, followed by detergent of low pH, finally wiping with IMS. VHP is an established process for biological control in isolators and may also be considered, together with other measures, for the control of contamination by drugs that are readily oxidized, such as the anthracyclines.

ACKNOWLEDGEMENTS

The authors wish to acknowledge the expert help and advice given on the cleaning chemistries by Mildred R Bernardo, MS Senior Scientist, Steris Corporation, St Louis, USA.

REFERENCES

- 1 Connor TH, Anderson RW, Sessink PJM, *et al.* Surface contamination with antineoplastic agents in six cancer treatment centres in Canada and the United States. *Am J Health Sys Pharm* 1999; 56: 1427–32.

- 2 Floridia L, Pietropaolo AM, Tavazzani M, *et al.* High-performance liquid chromatography of methotrexate for environmental monitoring of surface contamination in hospital departments and assessment of occupational exposure. *J Chromatogr B* 1999; 726: 95–103.
- 3 Hoy RH, Stump MS. Effect of an air-venting filter device on aerosol production from vials. *Am J Hosp Pharm* 1984; 41: 324–26.
- 4 Micoli G, Turci R, Arpellini M, Minoia C. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B* 2001; 750: 25–32.
- 5 Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. *Am J Health Sys Pharm* 2002; 59: 956–61.
- 6 Sessink PJM, Anzion RBM, Petra HH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. *Pharm Weekbl Sci Ed* 1992; 14: 16–22.
- 7 Sessink PJM, Boer KA, Scheefhals APH, *et al.* Occupational exposure to antineoplastic agents at several departments in a hospital. *Int Arch Occup Environ Health* 1992; 64: 105–12.
- 8 Spivey PJ, Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. *Hosp Pharm* 2003; 38: 135–39.
- 9 Vandenbroucke J. Cytotoxic agents and contamination in hospitals: a monitoring program in Uz Gent. *J Oncol Pharm Pract* 2001; 6: 146–52.
- 10 Selevan SG, Lindbohm M-L, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. *New Engl J Med* 1985; 313: 1173–77.
- 11 Shortridge LA, Lemasters GK, Valanis B. Menstrual cycles in nurses handling antineoplastic drugs. *Cancer Nurs* 1995; 18: 439–44.
- 12 Skov T, Maarup B, Olsen J, *et al.* Leukemia and reproductive outcome among nurses handling antineoplastic drugs. *Br J Int Med* 1992; 49: 855–61.
- 13 Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents; self-reported miscarriages and stillbirths among nurses and pharmacists. *J Occup Environ Med* 1999; 41: 632–38.
- 14 NIOSH Alert. 2004. Retrieved from <http://www.cdc.gov/niosh/docs/2004-165/>
- 15 World Health Organisation. Laboratory decontamination and destruction of carcinogens in laboratory wastes; some antineoplastic agents. International Agency for Research on Cancer, 1985 (IARC publication No.: 73 2004).
- 16 Castegnaro M, De Meo MD, Laget M, *et al.* Chemical degradation of wastes of antineoplastic agents. 2: Six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin and daunorubicin. *Int Arch Occup Environ Health* 1997; 70: 378–84.
- 17 Hansel S, Castegnaro M, Sportouch MH, *et al.* Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. *Int Arch Occup Environ Health* 1997; 69: 109–14.
- 18 Klapes NR, Vesley D. Vapor-phase hydrogen peroxide as a surface decontaminant and sterilant. *Appl Environ Microbiol* 1990; 56: 503–506.
- 19 Krause J, McDonnell G, Riedesel H. Biodecontamination of animal rooms and heat sensitive equipment with vaporised hydrogen peroxide. Contemporary topics. *Am Assoc Lab Anim Sci* 2001; 40:18–21.
- 20 Analytical method for cyclophosphamide. Clinical Pharmacology Laboratory, Pharmacy Department, Bath University, 2002.
- 21 Analytical method for doxorubicin. Clinical Pharmacology Laboratory, Pharmacy Department, Bath University, 2004.
- 22 Roberts S, Sewell GJ. Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump. *J Oncol Pharm* 2003; 9: 2–3.
- 23 Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromatography and gas chromatographic methods. Applications to pharmacokinetics. *J Chromatogr B* 1996; 686: 3–10.
- 24 Allwood M, Stanley A, Wright P eds. *The cytotoxics handbook*, fourth edition. Radcliffe Medical Press, 2006.
- 25 Trissel LA. *The handbook of injectable drugs*. American Society of Health System Pharmacists 2005.
- 26 McDonnell G. Peroxygens and other forms of oxygen. In Zhu P ed. *New biocides development: the combined approach of chemistry and microbiology*. ACS Books, Oxford University Press, Washington D.C. 2006.
- 27 Connors KA, Amidon GL, Stella J. *Chemical stability of pharmaceuticals. A handbook for pharmacists*, second edition. J. Wiley & Sons Inc 1986.